SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001193125-22-127820
Filing Date
2022-04-28
Accepted
2022-04-28 16:50:09
Documents
1
Group Members
JULIET TAMMENOMS BAKKERLONGITUDE VENTURE PARTNERS III, L.P.PATRICK G. ENRIGHT

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d342065dsc13da.htm SC 13D/A 78242
  Complete submission text file 0001193125-22-127820.txt   79953
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Subject) CIK: 0001693011 (see all company filings)

IRS No.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91586 | Film No.: 22867580
SIC: 2834 Pharmaceutical Preparations

Mailing Address 800 EL CAMINO, SUITE 220 MENLO PARK CA 94025
Business Address 800 EL CAMINO, SUITE 220 MENLO PARK CA 94025 650-845-5700
Longitude Capital Partners III, LLC (Filed by) CIK: 0001713663 (see all company filings)

IRS No.: 811668051 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A